PF-07220060 CDK4 inhibitor

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

days

PFEPhase 2$142.7B

PF-07220060 CDK4 inhibitor Phase 2 Results Expected

PF-07220060 CDK4 inhibitor• Advanced or Metastatic Breast Cancer333

Mar 31Estimated

00%

Competitive Landscape

0 competitors in Advanced or Metastatic Breast Cancer

Drug Information

Target Indication

Advanced or Metastatic Breast Cancer

Clinical Trial

Last updated: 1/8/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Related Pipeline

Vaccines, Pneumococcal

Renal Transplantation

Diabetes Mellitus

Major Depressive Disorder

Complicated Intra-abdominal Infections